How Devices Precisely Track Glucose Across Body Compartments

This patent describes a method for accurately estimating a person's blood glucose by accounting for the natural time delay in how glucose moves between different body fluids, like blood and the fluid around cells, to better control insulin pumps.

What it covers

This patent describes a method and system for more accurately monitoring an analyte, such as glucose (Claim 3), in a person's body. It uses a sensor (Claim 7) to measure the analyte in a 'second physiological compartment,' like interstitial fluid (Claim 3). A controller or processor (Claim 1, 7) then estimates the time delay, or 'latency,' for the analyte to move between this second compartment and a 'first physiological compartment,' such as blood plasma (Claim 3). This estimation relies on at least one blood glucose reference sample (Claim 1, 7). The system then 'compensates' for this latency when calculating the analyte's concentration in the first compartment. This compensation involves accumulating differences between sensor readings and an offset, and combining this with a term that includes the estimated latency (Claim 1). Based on this more accurate estimate, the controller generates commands for infusion pumps (Claim 1, 7), such as an insulin pump, to adjust treatment. For example, a continuous glucose monitor (CGM) measures glucose in interstitial fluid, and this patent helps the system predict the actual blood glucose level more precisely, even with the natural delay, to deliver the correct amount of insulin.

What it doesn't cover

• —Does not cover glucose monitoring systems that do not actively estimate and compensate for the time delay (latency) between glucose levels in different body compartments.
• —Does not cover systems that only measure glucose in a single physiological compartment without considering the transport latency between two distinct compartments.
• —Does not cover glucose monitoring systems that only display readings without generating commands for an infusion pump based on the estimated concentration.
• —Does not cover systems that do not use at least one blood glucose reference sample to help estimate the latency.
• —Does not cover compensation methods that do not involve accumulating difference values between a sensor signal and an offset, and combining this with a term including the estimated latency.

The clever bit

The clever part is explicitly estimating and then mathematically compensating for the natural time lag (latency) of an analyte, like glucose, as it moves between different body fluids. This allows for more accurate real-time estimation of blood glucose from a sensor placed in a different body compartment, which is crucial for automated treatment decisions.

Why it matters

Accurate glucose monitoring is critical for managing diabetes, especially for automated insulin delivery systems. The body's fluids, like blood and interstitial fluid, don't change glucose levels at the exact same time. This patent improves the precision of continuous glucose monitoring by accounting for these natural delays, leading to more timely and effective treatment decisions. This directly impacts patient safety and health outcomes by reducing the risk of dangerously high or low blood sugar.

Real-world examples

• 1.Medtronic MiniMed systems
• 2.Automated insulin delivery systems (artificial pancreas systems)
• 3.Continuous Glucose Monitoring (CGM) devices integrated with insulin pumps